Following the 2015/16 BioInnovate program, Fergal created Capri Medical, a company devoted to developing an injectable neurostimulation platform for chronic pain and various other neurological indications. The company leveraged seed funding from the Enterprise Ireland Commercialisation Fund to develop prototype devices and initial preclinical studies. Building on this success, in 2020 Capri Medical was awarded 2nd place in Europe’s flagship EIC program and a €2.5million grant helped the company scale its team and IP. In 2022 the company was again successful in winning an additional €2m grant funding within a €6.5m EC Horizon project to begin First in Human studies.